NYSEMKT:PHGE BiomX (PHGE) Stock Price, News & Analysis $0.56 -0.18 (-24.90%) Closing price 08/15/2025 03:55 PM EasternExtended Trading$0.54 -0.02 (-2.88%) As of 08/15/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesInsider TradesOwnershipSEC FilingsBuy This Stock About BiomX Stock (NYSEMKT:PHGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BiomX alerts:Sign Up Key Stats Today's Range$0.72▼$0.7850-Day Range$0.39▼$0.5952-Week Range$0.34▼$2.40Volume53,300 shsAverage Volume347,190 shsMarket Capitalization$14.53 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingBuy Company Overview BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. Read More BiomX Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScorePHGE MarketRank™: BiomX scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiomX has received no research coverage in the past 90 days.Read more about BiomX's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BiomX are expected to grow in the coming year, from ($0.44) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PHGE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for PHGE. News and Social Media2.1 / 5News Sentiment-0.16 News SentimentBiomX has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BiomX this week, compared to 0 articles on an average week.Search Interest7 people have searched for PHGE on MarketBeat in the last 30 days. MarketBeat Follows3 people have added BiomX to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.17% of the stock of BiomX is held by insiders.Percentage Held by Institutions40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BiomX's insider trading history. Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGE Stock News HeadlinesBiomX Inc. (PHGE) Q2 2025 Earnings Call TranscriptAugust 13 at 12:06 PM | seekingalpha.comBiomX Reports Second Quarter 2025 Financial Results and Provides Program UpdatesAugust 13 at 6:30 AM | globenewswire.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)What to Expect from BiomX's EarningsAugust 12, 2025 | benzinga.comBiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025August 6, 2025 | globenewswire.comBiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapyJuly 14, 2025 | investing.comBiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis TreatmentJuly 14, 2025 | msn.comPHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron'sJuly 14, 2025 | barrons.comSee More Headlines PHGE Stock Analysis - Frequently Asked Questions How have PHGE shares performed this year? BiomX's stock was trading at $0.7301 at the start of the year. Since then, PHGE shares have decreased by 24.0% and is now trading at $0.5550. How were BiomX's earnings last quarter? BiomX Inc. (NYSEMKT:PHGE) posted its quarterly earnings results on Monday, May, 15th. The company reported ($2.00) earnings per share for the quarter, missing analysts' consensus estimates of ($1.80) by $0.20. When did BiomX's stock split? BiomX's stock reverse split on Monday, August 26th 2024.The 1-10 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are BiomX's major shareholders? Top institutional shareholders of BiomX include Warberg Asset Management LLC (0.31%). Insiders that own company stock include Israel Biofund Gp Limi Orbimed, Chidozie Ugwumba and Assaf Oron. View institutional ownership trends. How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), NVIDIA (NVDA), Zomedica (ZOM), Insulet (PODD) and Ford Motor (F). Company Calendar Last Earnings5/15/2023Today8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEMKT:PHGE CIK1739174 Webwww.biomx.com Phone972 7 23942377FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for BiomX$21.00 High Price Target$21.00 Low Price Target$21.00 Potential Upside/Downside+3,683.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.32 million Net MarginsN/A Pretax MarginN/A Return on Equity-127.82% Return on Assets-56.50% Debt Debt-to-Equity Ratio0.51 Current Ratio2.84 Quick Ratio2.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book0.79Miscellaneous Outstanding Shares26,176,000Free Float44,044,000Market Cap$14.53 million OptionableNot Optionable Beta1.42 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSEMKT:PHGE) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BiomX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.